An update on the long-acting insulin analogue glargine

被引：26
|
作者：
Thisted, Henriette
Johnsen, Soren Paaske
Rungby, Jorgen
机构：
[1] Aarhus Univ Hosp, Dept Clin Epidemiol, DK-8000 Aarhus C, Denmark
[2] Aarhus Univ Hosp, Dept Endocrinol C, DK-8000 Aarhus C, Denmark
[3] Univ Aarhus, Dept Pharmacol, Aarhus, Denmark
来源：
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | 2006年 / 99卷 / 01期
关键词：
D O I：
10.1111/j.1742-7843.2006.pto_352.x
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
For both type 1 and type 2 diabetes, tight glycaemic control is vital to reduce the risk of long-term complications. However, this must be achieved with minimal risk of hypoglycaemia. Glargine is a new long-acting insulin analogue with an action profile designed to overcome this and has now been in clinical use for a number of years. In many countries glargine is widely used. Here we present an update on the clinical information available on glargine with respect to glycaemic control, the risk of hypoglycaemia and quality of life in both type 1 and type 2 diabetes.
引用
收藏
页码：1 / 11
页数：11
相关论文
共 50 条
  • [41] Comparison of intracellular signaling properties induced by the long-acting insulin analogues glargine and detemir in cultured cells
    Sasaoka, Toshiyasu
    Azegami, Mari
    Sugiyama, Maine
    Tsuneki, Hiroshi
    Wada, Tsutomu
    DIABETES, 2006, 55 : A481 - A481
  • [42] Comparison of intracellular signaling properties induced by the long-acting insulin analogues glargine and detemir in cultured cells
    Sasaoka, T.
    Tsuneki, H.
    Wada, T.
    DIABETOLOGIA, 2007, 50 : S234 - S234
  • [43] PROGRANULIN AND CHEMERIN PLASMA LEVEL IN OBESE PATIENTS WITH TYPE 2 DIABETES TREATED WITH A LONG-ACTING INSULIN ANALOGUE AND PREMIXED INSULIN ANALOGUE
    Waluga-Kozlowska, E.
    Kuznik-Trocha, K.
    Komosinska-Vassev, K.
    Olczyk, P.
    Jura-Poltorak, A.
    Winsz-Szczotka, K.
    Telega, A.
    Ivanova, D.
    Strzoda, W.
    Zimmermann, A.
    Janik, M.
    Olczyk, K.
    Waluga, M.
    JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2021, 72 (06): : 895 - 903
  • [44] Long-acting GnRH analogue versus short-acting GnRH analogue in long protocol for ICSI procedure
    Shalabi, A
    Fedah, M
    Qahwaji, L
    HUMAN REPRODUCTION, 1999, 14 : 365 - 365
  • [45] Long-Acting Insulin Glargine Titration Web Tool (LTHome) vs. Enhanced Usual Therapy of Glargine Titration (INNOVATE Trial)
    Bajaj, Harpreet S.
    Venn, Karri
    Ye, Chenglin
    Aronson, Ronnie
    DIABETES, 2015, 64 : A258 - A258
  • [46] Long-acting interferon for myeloproliferative neoplasms - an update
    Pai, Sachin Gopalkrishna
    Kaplan, Jason Benjamin
    Giles, Francis Joseph
    EXPERT REVIEW OF HEMATOLOGY, 2016, 9 (10) : 915 - 917
  • [47] Insulin detemir is an effective long-acting human insulin analogue for the treatment of type 1 and 2 diabetes mellitus
    不详
    Drugs & Therapy Perspectives, 2005, 21 (9) : 1 - 4
  • [48] Long-acting insulin analogue NN304 has similar transendothelial transport to porcine insulin.
    Dea, MK
    HamiltonWessler, M
    Ader, M
    Poulin, RA
    Moore, D
    Markussen, J
    DIABETES, 1997, 46 : 634 - 634
  • [49] Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: Comparisons to insulin and IGF-I
    Ciaraldi, TP
    Carter, L
    Seipke, G
    Mudaliar, S
    Henry, RR
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (12): : 5838 - 5847
  • [50] How long should a long acting insulin analogue be?
    Mathieu, Chantal
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2013, 100 (02) : 170 - 172
12345